SCHEMBL4581101

SCHEMBL4581101

O=C(O)c1ccc2cncc(NCc3ccncc3)c2n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 9/20 0.49
KDM4E B2RXH2 3/20 0.49
KDM6B O15054 1/20 0.49
KDM4A O75164 1/20 0.49
KDM4D Q6B0I6 1/20 0.49
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 1/20 0.46
KDM5B Q9UGL1 1/20 0.45
HDAC6 Q9UBN7 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
POLB P06746 1/20 0.41
ASPH Q12797 2/20 0.41
RIOX2 Q8IUF8 2/20 0.41
KDM8 Q8N371 2/20 0.41
ADRA2C P18825 1/20 0.39
P4HTM Q9NXG6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4582783 0.86 KDM4E (0.49) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL4581250 0.81 HDAC3 (0.47) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL4579533 0.80 ADRA2A (0.47) KDM4CKDM4EKMT2AMEN1ADRA2C
SCHEMBL4581648 0.78 AURKA (0.47) KDM4CKDM4EKMT2AMEN1KDM5B
SCHEMBL4581093 0.78 KDM4E (0.58) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL4580096 0.77 MMP2 (0.42) KDM4CKDM4EKMT2A
SCHEMBL1714819 0.73 KDM4C (0.85) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL4580845 0.72 MMP2 (0.46) KDM4CKDM4EKMT2AADRA2CP4HTM
SCHEMBL4579902 0.71 CCNC (0.43) KDM4EKMT2A
SCHEMBL4582757 0.71 GSK3A (0.42) KDM4EKMT2AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US claimed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US claimed
EP-1773834-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES Serenex, Inc. (US) 2007-04-18 EP claimed
WO-2006017672-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES SERENEX INC. (US) 2006-02-16 WO claimed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives CCNA1, FOXM1, CCNA2 KDM4C 2536/4885KDM4E 3744/4885KDM6B 3038/4885
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 KDM4C 2536/4885KDM4E 3744/4885KDM6B 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.